Ultragenyx Pharmaceutical reported $136 million in total revenue for Q1 2026, with key products Crysvita and Dojolvi contributing $93 million and $18 million respectively. The company reaffirmed its 2026 revenue guidance of $730 million to $760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Ultragenyx highlighted promising long-term Phase 1/2 data for GTX-102 in treating Angelman syndrome, with Phase 3 results expected in the second half of 2026. The company is also progressing with regulatory reviews for gene therapies DTX401 and UX111, targeting approvals later this year, and aims for profitability in 2027.
Perplexity AI CEO Aravind Srinivas shared lessons from Nvidia's Jensen Huang and Tesla's Elon Musk, highlighting Huang's mindset of running Nvidia as if it could fail within 30 days despite its $5 trillion valuation and advanced technology. Srinivas ...
Meta Platforms introduced an AI-powered feature called "AI Mode" within Facebook Search, which uses Meta's AI model Muse Spark to provide answers from public content rather than traditional search results. This innovation could generate over $10 bill...
Cuprina Holdings shares surged 111.84% intraday following FDA 510(k) clearance for its MEDIFLY Maggots wound care product, the first maggot debridement therapy using Lucilia cuprina species approved in the U.S. The product treats non-healing necrotic...
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
